- Home
- PSTV vs ICCM Comparison
PSTV vs ICCM Comparison
Compare PSTV & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSTV | ICCM |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 41.4M |
| IPO Year | 2016 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PSTV | ICCM |
|---|---|---|
| Price | $5.21 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $55.00 | $2.50 |
| AVG Volume (30 Days) | 130.2K | ★ 1.0M |
| Earning Date | 05-29-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,213,000.00 | N/A |
| Revenue This Year | $13.20 | $139.51 |
| Revenue Next Year | $261.48 | $75.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.13 | $0.13 |
| 52 Week High | $8.00 | $5.69 |
Technical Indicators
Market Signals| Indicator | PSTV | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 58.94 |
| Support Level | $0.37 | $0.52 |
| Resistance Level | $6.65 | $5.69 |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | -0.14 | 0.16 |
| Stochastic Oscillator | 3.45 | 41.24 |
Price Performance
Historical ComparisonAbout PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.